)

Illumina (ILMN) investor relations material
Illumina Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Executive summary
- Q3 2025 revenue was $1.08 billion, flat year-over-year globally, with growth outside China offsetting a 31% decline in Greater China; clinical segment drove acceleration and NovaSeq X transition exceeded targets, with over 75% of high-throughput gigabases and over 50% of revenue on the X platform. 
- Non-GAAP operating margin expanded to 24.5% (up 190 basis points), and non-GAAP diluted EPS rose 18% year-over-year to $1.34, both above guidance. 
- Strong clinical market momentum, with sequencing consumables revenue growing at a high single-digit to 12% rate year-over-year ex-China, while research and applied consumables declined high single digits. 
- Resilience in Greater China, with revenue ahead of guidance despite export restrictions, but still down 31% year-over-year. 
- GRAIL was spun off in June 2024; historical results include GRAIL up to that date. 
Financial highlights
- Sequencing consumables revenue was $747 million, flat year-over-year, but up 3% ex-China; clinical segment grew 12% while research & applied declined 8%. 
- Sequencing instruments revenue was $107 million, up 3% year-over-year and 6% ex-China. 
- Sequencing service and other revenue was $147 million, down 2–3% year-over-year due to timing of strategic partnership revenues. 
- Non-GAAP gross margin was 69.2%, impacted by tariffs by 220 basis points year-over-year; GAAP gross margin was 67.6%. 
- Free cash flow was $253 million; cash from operations was $284 million; $120 million spent on share repurchases. 
Outlook and guidance
- FY25 revenue guidance is $4.27–$4.31 billion, with total revenue growth of 0.5%–1.5% constant currency, and 2.5%–3% growth ex-China; Greater China revenue expected to decline 4%–6%. 
- Sequencing consumables growth ex-China guided to 2.5%–3% for 2025. 
- Non-GAAP operating margin guidance increased to 22.75%–23% for 2025. 
- Non-GAAP diluted EPS guidance raised to $4.65–$4.75, reflecting 13% growth year-over-year. 
- 2026 outlook: clinical to remain primary growth driver, research to stay muted, multi-omics launches to contribute as markets recover. 
Next Illumina earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
Frequently asked questions
- Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free. 
- Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions. 
- Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more. 
Explore our global coverage
)
)